|Day Low/High||38.75 / 40.66|
|52 Wk Low/High||24.33 / 50.05|
- Olorinab demonstrated a statistically significant improvement in abdominal pain over 8 weeks of treatment
SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
SAN DIEGO, Aug. 28, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
- Initiated ADVANCE Phase 3 Program for Ralinepag in Pulmonary Arterial Hypertension (PAH)
SAN DIEGO, July 30, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its second quarter 2018 financial results and provide a corporate update on Monday, August 6, 2018, after the close of the U.
SAN DIEGO, July 10, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas, today announced the appointment of Kieran T.
Investors in Arena Pharmaceuticals Inc saw new options begin trading this week, for the September 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 86 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
The S&P 500 has shown the same pattern for three consecutive days.
The best way to deal with it is to keep on hunting for individual stocks.
It is two totally different markets when you compare the small-cap action to the big-cap indices.
We are seeing a focus on finding smaller names that may offer interesting valuations and stories.
This underperformance is being caused by pockets of weakness in bigger-cap names.
The key for the overall market now is that it hold above today's early lows.
There is no question that we are becoming extended and ripe for some profit taking.
Sector charts should shape up as worries about prices are finally put to rest.
Overall it is still a positive day but the action is sloppy.
Finding good setups in individual stocks is still challenging as there simply isn't a lot of strong momentum.
The challenge of this market is that the upward moves have not been well sustained.
- Arena's non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine's expertise in developing products for genitourinary disorders
Jim Cramer focuses on Walgreens Boots Alliance, Arena Pharmaceutical, Dominion Energy, Tower Semiconductor, Idexx, LexinFintech Holdings and more.
It's not all about the bond market, says Jim Cramer. The central issues here are trade, tariffs and most important, the stocks themselves, like Facebook and Amazon.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.